Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer by Nonomura, N et al.
Decreased number of mast cells infiltrating into needle biopsy
specimens leads to a better prognosis of prostate cancer
N Nonomura*,1, H Takayama
1, K Nishimura
1, D Oka
1, Y Nakai
1, M Shiba
1, A Tsujimura
1, M Nakayama
1,
K Aozasa
2 and A Okuyama
1
1Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan;
2Department of Pathology, Osaka University Graduate School of
Medicine, Osaka, Japan
Mast cell infiltration is often observed around human tumours. Inflammatory cells such as macrophages, neutrophils and mast cells
infiltrating around tumours are known to contribute to tumour growth; however, the clinical significance of mast cell invasion in
prostate cancer (PCa) has not been investigated. Mast cell infiltration was evaluated in 104 patients (age range, 45–88 years; median,
72 years), who underwent needle biopsy of the prostate and were confirmed to have PCa. Needle biopsy specimens of prostate
were sliced into 5-mm-thick sections and immunostained for mast cells with monoclonal antibody against mast cell-specific tryptase.
Mast cells were counted systematically under a microscope ( 400 magnification), and the relations between mast cell numbers and
clinicopathologic findings were evaluated. The mast cell count was evaluated for prognostic value by multivariate analysis. Mast cells
were immunostained around the cancer foci. The median number of mast cells in each case was 16. The mast cell count was higher
around cancer foci in patients with higher Gleason scores than in those with low Gleason scores. The mast cell number correlated
well with clinical stage (Po0.001). Prostate-specific antigen-free survival of patients with higher mast cell counts was better than that
in patients with lower mast cell counts (Po0.001). Multivariate analysis revealed that mast cell count was a significant prognostic
factor (Po0.005). The number of mast cells infiltrating around cancer foci in prostate biopsy specimens can be a significant prognostic
factor of PCa.
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Prostate cancer (PCa) is one of the most common malignancies
and is now the second leading cause of cancer-related death in men
in the United States (Parker et al, 1996; Parkin et al, 2002). Several
prognostic factors related to the clinicopathologic features have
been described. Among them, serum prostate-specific antigen
(PSA) level, T stage and Gleason score are considered very
important prognostic factors (Partin et al, 1997; Pound et al, 1997;
Kattan et al, 1998; Hull et al, 2002). However, only a few factors
that represent the host response which is composed of various
inflammatory cells have been reported as prognostic factors for
PCa so far (Irani et al, 1999; Wise et al, 2000; Schulz et al, 2007).
Tumour cells are surrounded by inflammatory cells such as
macrophages, lymphocytes, neutrophils and mast cells. Inflamma-
tory cell infiltrates, particularly macrophages, may contribute to
tumour progression by producing angiogenic factors (Gruber et al,
1995; Jenkins et al, 1995). The role of mast cells in tumour growth
has been studied extensively in experimental tumours (Fisher and
Fisher, 1965; Tanooka et al, 1982; Burtin et al, 1985), however, the
significance of mast cell infiltration around human tumours has
not been well studied, even though accumulation of mast cells
around tumours was first reported a decade ago (Dimitriadou and
Koutsilieris, 1997). Most studies have shown that mast cells
prevent tumour growth (Farram and Nelson, 1980; Henderson
et al, 1981; Ghiara et al, 1985; Benyon et al, 1991). In contrast, in a
heterocyclic amine-induced rat PCa model, Nakai et al (2007)
reported increased infiltration of stromal mast cell in the ventral
prostate, with increased prostatic epithelial proliferation, suggest-
ing that mast cells may have beneficial roles in progression of PCa
(Nakai et al, 2007). The significance of mast cell accumulation
around PCa has not been investigated extensively (Gupta, 1970;
Sari et al, 1999; Aydin et al, 2002). In the present study, the
viability of mast cell accumulation around PCa as a prognostic
factor was examined.
MATERIALS AND METHODS
Patients
One hundred and four patients diagnosed with local PCa by
transrectal needle biopsy at Osaka University Hospital between
1997 and 2000 were selected for the present study. Written
informed consent form approved by our institute was obtained.
The ages of the patients ranged from 45 to 88 years (median, 72
years). A diagnosis of PCa was made by histologic examination of
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sthe biopsy specimens. Clinical stage was defined according
to the American staging system (Sobin and Wittekind,
1997) through digital rectal examination (DRE), transrectal
ultrasonography, chest X-ray, computed tomography, magnetic
resonance imaging and bone scintigram. Serum PSA levels
measured by immunoenzymatic assay ranged from 4.3 to
316.8ngml
 1 (median, 16.9ngml
 1). Clinical stage was distributed
as follows: 20 cases (19.2%) in stage T1, 46 cases (44.2%) in stage
T2, 36 cases (34.6%) in stage T3 and two cases (1.9%) in T4
(Table 1). Biopsy specimens were fixed in 10% neutral buffered
formalin and routinely processed for paraffin embedding. Serial
5-mm-thick sections were cut, stained with haematoxylin and
reviewed by one pathologist to determine the Gleason score
(Gleason and Mellinger, 1974).
Seventy-five patients underwent radical prostatectomy and
remaining 29 received irradiation therapy as initial therapy. No
patients received brachytherapy. After initial therapy, patients
were followed up with periodic evaluations of DRE, serum PSA and
imaging findings. Progression of PCa was defined as an elevated
PSA at three consecutive measurements (PSA failure), the
appearance of new lesion, reappearance of any lesion that had
disappeared or clear worsening of non-measurable disease.
Immunohistochemical analyses
Mast cells were stained immunohistochemically with a monoclonal
antibody against tryptase specific to mast cells (TransGenic Inc.,
Kobe, Japan). Immunohistochemistry of paraffin sections was
carried out with an LSAB kit (Dako, Glostrup, Denmark). For
systematic counting, three ocular measuring fields, each with a real
area of 0.06175mm
2, were randomly chosen under a microscope at
a power of  400 within a section. If the cancer foci were too small
to obtain three independent fields, mast cells were counted in only
one or two fields.
Statistical analyses
Statistical analyses were performed with StatView software (SAS
Institute Inc., Cary, NC, USA). Correlation between mast cell count
by immunohistochemistry and clinicopathologic parameters was
evaluated with the w
2 test (Table 2). The follow-up period for
survivors measured from the date of start of therapy, ranged from
2.7 to 181.5 months (mean, 54.5 months). Progression-free survival
rate was calculated by the Kaplan–Meier method, and differences
in survival curves were estimated with the Log-rank test (Figures 2
and 3). Independent prognostic factors were analysed by Cox
proportional hazards regression model in a stepwise manner.
Po0.05 was considered statistically significant.
RESULTS
Mast cell infiltration of PCa
Matriptase-positive cells (mast cells) were observed only around
the cancer foci (Figure 1). The median number of mast cells
infiltrating into the peritumoral area was 16 (range, 5–70). Of the
104 cases, 52 cases had a mast cell count higher than 16
(designated as ‘high MC group’), and the remaining 52 patients
had a mast cell count lower than 16 (low MC group).
Correlations between mast cell count and various
clinicopathologic factors
The correlations between mast cell count and various clinico-
pathologic factors are shown in Table 2. Statistical significance was
calculated by w
2 test. The mast cell count correlated positively with
clinical T (Po0.001) and with Gleason score (Po0.05, Gleason
score p6 vs 7; Po0.001, Gleason score p6 vs X8; Po0.05,
Gleason score 7 vs X8). Patients with PSA failure had significantly
higher mast cell counts than those with no PSA failure (Po0.001).
However, PSA level did not correlate significantly with mast cell
count.
Recurrence-free survival analysis of patients treated by
radical prostatectomy or irradiation therapy as initial
therapies
Progression-free survival rates of 104 patients who underwent
radical prostatectomy or irradiation therapy as initial therapies
were evaluated. The follow-up period ranged from 2.0 to 96.0
months (mean, 46.8 months). The disease-free survival time
ranged from 2.0 to 84.2 months (mean, 32.9 months). Progression-
free survival of the patients with low Gleason score (o8) was
significantly better than those with high Gleason score (X8), as
expected (Po0.005) (Figure 2A). The median progression-free
survival time of the patients with high Gleason scores was 56
months. But, the progression-free survival rate of the patients with
low Gleason score did not reach 50% during the observation
period. The significance of mast cell infiltration for progression-
Table 1 Patient characteristics
Median (range)
Age (years) 72 (45–88)
Prostate-specific antigen (ng/ml) 16.9 (4.3–316.8)
Gleason score
p6 49 (44.2%)
7 29 (27.9%)
X8 26 (25.0%)
Clinical T stage
Tp2 66 (63.4%)
TX3 38 (36.5%)
Total 104 (100%)
Table 2 Correlation between mast cell infiltration and clinicopathologic
factors
Clinicopathologic
factors
Number of patients
(%)
Mast cell
count
Mean (s.e.)
a P-value
Age (years)
o70 51 (49%) 20.35 (13.25) NS
X70 53 (51%) 20.11 (11.83)
PSA
b (ng/ml)
o20 54 (51.9%) 18.59 (10.08) NS
X20 50 (48.1%) 21.74 (14.29)
Gleason score (GS)
GSp6 49 (44.2%) 15.80 (8.03) o0.05
c
GS¼7 29 (27.9%) 20.98 (13.94) o0.001
d
GSX8 26 (25.0%) 27.74 (14.25) o0.05
e
Clinical T stage
pT2 66 (63.4%) 17.30 (8.26) o0.001
XT3 38 (36.5%) 25.10 (16.39)
PSA failure
+ 30 (28.8%) 27.56 (15.70) o0.001
  74 (71.2%) 16.67 (8.69)
NS, not significant.
aStandard error.
bProstate-specific antigen.
cGSp6 vs GS¼7.
dGSp6 vs GSX8.
eGS¼7 vs GSX8.
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MC group was significantly better than that of the high MC group
(Po0.0001) (Figure 2B). The median progression-free survival
time of the high MC group was 57 months. However, the median
progression-free survival time of the low MC group did not reach
50% during the observation period.
Recurrence-free survival of patients treated with androgen
deprivation therapy
Androgen deprivation therapy is a commonly used therapy for PCa
in Japan. Therefore, we examined progression-free survival of
patients who received only androgen deprivation therapy. The
progression-free survival in patients with low Gleason score or
patients in the low MC group was better than that of patients with
high Gleason score or in the high MC group (Po0.05) (Figure 3A
and B). The median progression-free survival time of the patients
with high and low Gleason scores were 30 and 68 months,
respectively. The median progression-free survival of the high MC
group was 57 months, but the progression-free survival rate of the
low MC group did not reach 50% during the observation period.
Cox multivariate analysis for prognostic factors
Results of Cox multivariate analysis are shown in Table 3. Mast cell
infiltration (mast cell count 416), Gleason score (47) and
extraprostatic extension (positive) were significant factors for
progression-free survival. However, mast cell infiltration had the
lowest P-value and the highest hazard ratio (2.726).
DISCUSSION
It has been long recognized that inflammatory cell infiltration is
often seen around many types of tumours (Dimitriadou and
Koutsilieris, 1997). Most attention focused on the role of
infiltration lymphoid cells such as tumour-infiltrating lympho-
cytes, which represent the host immune reaction against the
tumour (Romero et al, 1998; Molldrem et al, 2000; Zhang et al,
2003). There have been a number of reports regarding mast cell
infiltration around a variety of human and experimentally induced
tumours (Ueda et al, 1988; Dimitriadou and Koutsilieris, 1997;
Takanami et al, 2000; Ribatti et al, 2004; Tuna et al, 2006).
In general, peripheral distribution of mast cells around an
experimentally induced tumour has been recognized as playing a
protective role against the tumours (Farram and Nelson, 1980;
Tanooka et al, 1982; Burtin et al, 1985). In these tumours, mast
cells and their degranulation products (histamine, serotonin and
heparin) have been reported to be involved in tumour inhibition
(Tharp et al, 1989; Benyon et al, 1991). It has been reported that
the incidence of metastases as well as the appearance of tumours
correlates inversely with tissue histamine level and mast cell count
(Burtin et al, 1985). Interestingly, isolated mast cells were shown to
inactivate tumour cells selectively in vitro (Henderson et al, 1981).
These findings suggest that mast cells may play a role in inhibiting
tumour metastases and suppressing growth of primary tumours.
The protective roles of mast cell infiltration have been reported
in soft tissue sarcomas in both human and animal models (Ueda
et al, 1988).
Figure 1 Immunostaining of mast cells with monoclonal antibody against
mast cell-specific tryptase in prostate biopsy specimens. (A) A case with
high-level mast cell infiltration. (B) A case with low-level mast cell
infiltration. Bar, 20mm.
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Figure 2 Progression-free survival of PCa patients stratified by Gleason
score (GS) or mast cell infiltration. (A) Progression-free survival of PCa
patients with high and low Gleason scores. (B) Progression-free survival of
PCa patients in high and low mast cell (MC) counts. High Gleason score,
GSX8; low Gleason score, GSp7. High MC group, 416; low MC group,
p16.
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malignancies, some studies have suggested promote that
mast cells tumour progression. For instance, mast cell infiltration
correlates well with tumour angiogenesis and metastases in
gastric cancer (Yano et al, 1999), colorectal cancer (Lachter et al,
1995), pulmonary adenocarcinoma (Takanami et al, 2000)
and renal cell carcinoma (Tuna et al, 2006). In PCas, mast
cell infiltration correlates with poor prognosis, suggesting
that mast cells may promote tumour progression. Interestingly,
in our series of studies, a low mast cell count was associated
with longer recurrence-free survival of the patients receiving
hormonal therapies. In some immunohistochemical studies,
significant associations between mast cell number and microvessel
density were reported (Takanami et al, 2000; Tuna et al,
2006). Mast cells are known to produce several mediators of
angiogenesis, including fibroblast growth factor (FGF)-2, vascular
endothelial cell growth factor (VEGF), transforming growth
factor (TGF)-b and interleukin (IL)-8 (reviewed by Ribatti et al,
2004). These factors are all involved both in normal as well
as tumour-associated angiogenesis. In addition to these angiogenic
factors, mast cells also produce proteolytic enzymes such as
matrix metalloproteinase (MMP)-2 and -9, and tryptase (Fang
et al, 1999; Vincent et al, 2000; Di Girolamo et al, 2006). These
factors are known to promote invasion of cancer cells into
interstitial stromal tissue. Moreover, tryptase is one of the
proteolytic enzymes produced specifically by mast cells. In the
present study, we stained mast cells in prostate biopsy specimens
with antibody against mast cell-specific tryptase. Mast cell-specific
tryptase may also promote cancer cell invasion (Stack and
Johnson, 1994; Blair et al, 1997). Because microvessels are usually
very sparse in prostate biopsy specimens, the correlation between
microvessels and mast cell infiltration was not examined in the
present study.
Gupta (1970) first reported the presence of mast cells around
PCas. In our study, we observed mast cell aggregation at the
periphery of PCas, similar to previous reports (Sari et al, 1999;
Aydin et al, 2002). However, this is the first report that mast cell
infiltration around prostate tumours is a significant prognostic
factor for PCa.
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